FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
GHAPPcast24 Mar

FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?

Thank you to Johnson & Johnson for the support on this FAQ Video Module.

In this FAQ video module, Tedra Gray, a gastroenterology nurse practitioner at Sinai Chicago, breaks down the key differences between treat-through and randomized withdrawal clinical trial designs in inflammatory bowel disease (IBD). This educational overview explains how these two study designs impact the evaluation of new IBD therapies, including their role in assessing safety, efficacy, and long-term patient outcomes. Viewers will learn how treat-through trials randomize patients at baseline to receive either active treatment or placebo throughout the study, offering insights into real-world effectiveness from induction through maintenance. In contrast, randomized withdrawal designs focus on patients who initially respond to therapy, re-randomizing them to continue treatment or switch to placebo—allowing for more efficient study design, reduced placebo exposure, and a focus on maintenance of response.

This video also explores key considerations such as population selection, ethical implications, study objectives, and how these designs are applied in major Phase 3 IBD trials like ASTRO, GRAVITI, GALAXY, and QUASAR. Ideal for gastroenterology providers and advanced practice providers, this content provides practical insights into interpreting clinical trial data and optimizing treatment strategies in IBD.

For more expert-driven GI education, visit the GHAPP Digital Hub and GHAPP ACE app.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(164)

Linerixibat Medication Review

Linerixibat Medication Review

Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in p...

22 Sep 13min

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact o...

15 Sep 15min

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liv...

25 Aug 20min

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Jul 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Jun 17min

Populært innen Helse

fastlegen
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
fryktlos
rss-kunsten-a-leve
leger-om-livet
rss-skravla-gar
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-dagen-for-dagen
foreldreradet
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
treningsprat
hjernesterk
g-punktet
rss-loping-for-nybegynnere
sinnsyn
kjed-deg-i-sovn-verdens-kjedeligste-podcast